Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ono Pharmaceutical Ltd

ON4
Current price
11.9 EUR -0.1 EUR (-0.83%)
Last closed 1 930 JPY
ISIN JP3197600004
Sector Healthcare
Industry Drug Manufacturers - General
Exchange Frankfurt Exchange
Capitalization 901 288 923 358 JPY
Yield for 12 month -34.73 %
1Y
3Y
5Y
10Y
15Y
ON4
21.11.2021 - 28.11.2021

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan. Address: 8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

345 005.67 JPY

P/E ratio

7.5131

Dividend Yield

4.19 %

Current Year

+505 325 529 823 JPY

Last Year

+449 547 632 785 JPY

Current Quarter

+118 296 188 590 JPY

Last Quarter

+113 364 290 595 JPY

Current Year

+377 528 450 804 JPY

Last Year

+338 904 632 108 JPY

Current Quarter

+88 468 559 914 JPY

Last Quarter

+81 533 141 122 JPY

Key Figures ON4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 168 509 866 096 JPY
Operating Margin TTM 26.08 %
PE Ratio 7.5131
Return On Assets TTM 9.56 %
PEG Ratio
Return On Equity TTM 15.28 %
Wall Street Target Price 345 005.67 JPY
Revenue TTM 502 972 159 464 JPY
Book Value 1 735.38 JPY
Revenue Per Share TTM
Dividend Share 80.42 JPY
Quarterly Revenue Growth YOY 4.3 %
Dividend Yield 4.19 %
Gross Profit TTM 269 263 939 817 JPY
Earnings per share 255.43 JPY
Diluted Eps TTM 255.43 JPY
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 5.7 %
Profit Margin

Dividend Analytics ON4

Dividend growth over 5 years

81 %

Continuous growth

3 years

Payout Ratio 5 years average

36 %

Dividend History ON4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 80
Ex Dividend Date 27.09.2024
Forward Annual Dividend Yield 4.19 %
Last Split Factor 5:1
Payout Ratio 31.47 %
Last Split Date 29.03.2016
Dividend Date

Stock Valuation ON4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 7.5131
Forward PE 13.947
Enterprise Value Revenue 1.4007
Price Sales TTM 1.7919
Enterprise Value EBITDA 4.0576
Price Book MRQ 1.1306

Financials ON4

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ON4

For 52 weeks

1 906.01 JPY 2 893.76 JPY
50 Day MA 2 160.7 JPY
Shares Short Prior Month
200 Day MA 2 365.16 JPY
Short Ratio
Shares Short
Short Percent